Helix Biopharma Corp Stock Probability of Future Stock Price Finishing Over 1.29
| HBP Stock | CAD 0.97 0.03 3.00% |
Helix |
Helix BioPharma Target Price Odds to finish over 1.29
The tendency of Helix Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over C$ 1.29 or more in 90 days |
| 0.97 | 90 days | 1.29 | roughly 2.95 |
Based on a normal probability distribution, the odds of Helix BioPharma to move over C$ 1.29 or more in 90 days from now is roughly 2.95 (This Helix BioPharma Corp probability density function shows the probability of Helix Stock to fall within a particular range of prices over 90 days) . Probability of Helix BioPharma Corp price to stay between its current price of C$ 0.97 and C$ 1.29 at the end of the 90-day period is about 42.63 .
Assuming the 90 days trading horizon the stock has the beta coefficient of 3.51 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Helix BioPharma will likely underperform. Additionally Helix BioPharma Corp has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Helix BioPharma Price Density |
| Price |
Predictive Modules for Helix BioPharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Helix BioPharma Corp. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Helix BioPharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Helix BioPharma is not an exception. The market had few large corrections towards the Helix BioPharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Helix BioPharma Corp, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Helix BioPharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.13 | |
β | Beta against Dow Jones | 3.51 | |
σ | Overall volatility | 0.18 | |
Ir | Information ratio | -0.0046 |
Helix BioPharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Helix BioPharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Helix BioPharma Corp can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Helix BioPharma Corp had very high historical volatility over the last 90 days | |
| Helix BioPharma Corp has some characteristics of a very speculative penny stock | |
| Helix BioPharma Corp has high likelihood to experience some financial distress in the next 2 years | |
| Helix BioPharma Corp has accumulated 1.58 M in total debt. Helix BioPharma Corp has a current ratio of 0.36, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Helix BioPharma until it has trouble settling it off, either with new capital or with free cash flow. So, Helix BioPharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Helix BioPharma Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Helix to invest in growth at high rates of return. When we think about Helix BioPharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (9.26 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Helix BioPharma Corp has accumulated about 938 K in cash with (5.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Latest headline from news.google.com: Helix Biopharma Corp. Enters into Asset Purchase Agreement to Acquire Oral Gemcitabine Chemotherapy Compound - TheNewswire.ca |
Helix BioPharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Helix Stock often depends not only on the future outlook of the current and potential Helix BioPharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Helix BioPharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 44.5 M | |
| Cash And Short Term Investments | 1.1 M |
Helix BioPharma Technical Analysis
Helix BioPharma's future price can be derived by breaking down and analyzing its technical indicators over time. Helix Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Helix BioPharma Corp. In general, you should focus on analyzing Helix Stock price patterns and their correlations with different microeconomic environments and drivers.
Helix BioPharma Predictive Forecast Models
Helix BioPharma's time-series forecasting models is one of many Helix BioPharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Helix BioPharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Helix BioPharma Corp
Checking the ongoing alerts about Helix BioPharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Helix BioPharma Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Helix BioPharma Corp had very high historical volatility over the last 90 days | |
| Helix BioPharma Corp has some characteristics of a very speculative penny stock | |
| Helix BioPharma Corp has high likelihood to experience some financial distress in the next 2 years | |
| Helix BioPharma Corp has accumulated 1.58 M in total debt. Helix BioPharma Corp has a current ratio of 0.36, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Helix BioPharma until it has trouble settling it off, either with new capital or with free cash flow. So, Helix BioPharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Helix BioPharma Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Helix to invest in growth at high rates of return. When we think about Helix BioPharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (9.26 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Helix BioPharma Corp has accumulated about 938 K in cash with (5.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Latest headline from news.google.com: Helix Biopharma Corp. Enters into Asset Purchase Agreement to Acquire Oral Gemcitabine Chemotherapy Compound - TheNewswire.ca |
Other Information on Investing in Helix Stock
Helix BioPharma financial ratios help investors to determine whether Helix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.